Breaking News, Collaborations & Alliances

GSK, OBT in cancer pact

GlaxoSmithKline and Oxford BioTherapeutics have formed a strategic alliance to discover, develop and commercialize novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Oxford BioTherapeutics (OBT) have formed a strategic alliance to discover, develop and commercialize novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer. GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to in-license this monoclonal antibody and will ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters